jnj-75276617
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started May 19, 2021 (NCT04811560)
Timeline
Indications
Mechanism of action
KMT2A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCN(C(=O)c1cc(F)ccc1Oc1nncnc1N1CCC2(C1)CN([C@H](CCCN(C)CCOC)C(C)C)C2)C(C)C- Mol. weight
- 599.8 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314509 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07223814 | Phase 3 | Dec 31, 2025 | German-Austrian Acute Myeloid Leukemia Study Group, HOVON - Dutch Haemato-Oncology Association |
| NCT07295951 | Phase 1 | Nov 18, 2025 | — |
| NCT06852222 | Phase 3 | May 2, 2025 | — |
| NCT05521087 | Phase 1 | Dec 28, 2022 | — |
| NCT05453903 | Phase 1 | Oct 4, 2022 | — |
| NCT04811560 | Phase 1 | May 19, 2021 | Janssen Pharmaceutica NV |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| German-Austrian Acute Myeloid Leukemia Study Group | Academic/Hospital | 1 | 0 | 1 | 2025 |
| HOVON - Dutch Haemato-Oncology Association | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Janssen Pharmaceutica NV | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1